Physician profile
Tezo Karedan
NPI 1679887376
$917.40
in general payments reported to CMS, 2019-2025
19 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $62.68 · 2021: $63.83 · 2022: $131 · 2023: $26.23 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $136 · Food and Beverage: $60.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $135.50 |
| Food and Beverage | $60.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $156.31 | 2019-2023 | |
| Eisai INC. | $135.50 | 2025 | |
| Janssen Biotech, INC. | $115.73 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $103.55 | 2022 | |
| Merck Sharp & Dohme LLC | $63.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $57.10 | 2019-2021 | |
| Amgen INC. | $50.13 | 2019 | |
| Pfizer INC. | $40.75 | 2019 | |
| Abbvie INC. | $34.20 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $27.40 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.69 | 2019 | |
| Glaxosmithkline, LLC. | $18.56 | 2020 | |
| Celgene Corporation | $18.50 | 2019 | |
| Karyopharm Therapeutics INC. | $17.34 | 2021 | |
| Tesaro, INC. | $12.80 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $12.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.34 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $9.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tezo Karedan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.